Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00846586
Registration number
NCT00846586
Ethics application status
Date submitted
15/02/2009
Date registered
18/02/2009
Date last updated
18/08/2011
Titles & IDs
Public title
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
Query!
Scientific title
A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
Query!
Secondary ID [1]
0
0
CQAB149B2341
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
INTRUST1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease (COPD)
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Indacaterol 150 µg
Treatment: Drugs - Tiotropium 18 µg
Treatment: Drugs - Placebo to indacaterol
Experimental: Indacaterol 150 µg and tiotropium 18 µg - Patients inhaled indacaterol 150 µg and tiotropium 18 µg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting ß2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Active Comparator: Tiotropium 18 µg - Patients inhaled placebo to indacaterol 150 µg and tiotropium 18 µg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting ß2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Treatment: Drugs: Indacaterol 150 µg
Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Treatment: Drugs: Tiotropium 18 µg
Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
Treatment: Drugs: Placebo to indacaterol
Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of Treatment (Week 12)
Query!
Assessment method [1]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, 4, 6, and 8 hours post-dose at the end of the study (Week 12, Day 84). Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
Query!
Timepoint [1]
0
0
From 5 minutes to 8 hours post-dose at the end of treatment (Week 12, Day 84)
Query!
Secondary outcome [1]
0
0
Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Treatment (Week 12 + 1 Day, Day 85)
Query!
Assessment method [1]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of the study (Week 12 + 1 day, Day 85). The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
Query!
Timepoint [1]
0
0
24 hours post-dose at the end of treatment (Week 12 + 1 day, Day 85)
Query!
Secondary outcome [2]
0
0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose on Day 1
Query!
Assessment method [2]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
Query!
Timepoint [2]
0
0
From 5 minutes to 8 hours post-dose on Day 1
Query!
Secondary outcome [3]
0
0
Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 2
Query!
Assessment method [3]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 23 hours 10 minutes and 23 hours 45 minutes post-dose on Day 2. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
Query!
Timepoint [3]
0
0
24 hours post-dose on Day 2
Query!
Secondary outcome [4]
0
0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose on Day 1
Query!
Assessment method [4]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, and 4 hours post-dose on Day 1. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
Query!
Timepoint [4]
0
0
From 5 minutes to 4 hours post-dose on Day 1
Query!
Secondary outcome [5]
0
0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at the End of Treatment (Week 12)
Query!
Assessment method [5]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5 and 30 minutes; and 1, 2, 3, and 4 hours post-dose at the end of treatment (Week 12). Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.
Query!
Timepoint [5]
0
0
From 5 minutes to 4 hours post-dose at the end of treatment (Week 12)
Query!
Eligibility
Key inclusion criteria
- Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as
classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD]
Guidelines, 2007) and:
1. Smoking history of at least 10 pack-years
2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) = 65% and = 30%
of the predicted normal value
3. Post-bronchodilator FEV1/FVC (force vital capacity) < 70%
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid
treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening or
during the run-in period
- Patients who have had a respiratory tract infection within 6 weeks prior to screening
or during the run-in period
- Patients with a body mass index less than 15 or more than 40 kg/m^2
- Patients with concomitant pulmonary disease
- Patients with a history of asthma
- Patients with diabetes Type I or uncontrolled diabetes Type II
- Any patient with lung cancer or a history of lung cancer
- Patients with a history of certain cardiovascular comorbid conditions
Other protocol-defined inclusion/exclusion criteria applied to the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1134
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Novartis Investigator Site - Box Hill
Query!
Recruitment hospital [2]
0
0
Novartis Investigator Site - Clayton
Query!
Recruitment hospital [3]
0
0
Novartis Investigator Site - Garran
Query!
Recruitment hospital [4]
0
0
Novartis Investigator Site - Glebe
Query!
Recruitment hospital [5]
0
0
Novartis Investigator Site - Kogarah
Query!
Recruitment hospital [6]
0
0
Novartis Investigator Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
- Box Hill
Query!
Recruitment postcode(s) [2]
0
0
- Clayton
Query!
Recruitment postcode(s) [3]
0
0
- Garran
Query!
Recruitment postcode(s) [4]
0
0
- Glebe
Query!
Recruitment postcode(s) [5]
0
0
- Kogarah
Query!
Recruitment postcode(s) [6]
0
0
- Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Montana
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nevada
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Hampshire
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Jersey
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New York
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
North Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oklahoma
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oregon
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Pennsylvania
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Rhode Island
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Buenos Aires
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Cordoba
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Corrientes
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Mendoza
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Rosario
Query!
Country [36]
0
0
Colombia
Query!
State/province [36]
0
0
Barranquilla
Query!
Country [37]
0
0
Colombia
Query!
State/province [37]
0
0
Bogota
Query!
Country [38]
0
0
Colombia
Query!
State/province [38]
0
0
Medellin
Query!
Country [39]
0
0
Denmark
Query!
State/province [39]
0
0
Copenhagen
Query!
Country [40]
0
0
Denmark
Query!
State/province [40]
0
0
Fredericia
Query!
Country [41]
0
0
Denmark
Query!
State/province [41]
0
0
Silkeborg
Query!
Country [42]
0
0
Denmark
Query!
State/province [42]
0
0
Soeborg
Query!
Country [43]
0
0
Denmark
Query!
State/province [43]
0
0
Vejle
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Berlin
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Cottbus
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Donaustauf
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Dortmund
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Erfurt
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Frankfurt
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Gelnhausen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Grosshansdorf
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Hannover
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Heidelberg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Leipzig
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Mainz
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Neu-Ulm
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Neuss
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Potsdam
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Rostock
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Schwabach
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Schwetzingen
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Straussberg
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Wiesbaden
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Wuppertal
Query!
Country [65]
0
0
Guatemala
Query!
State/province [65]
0
0
Guatemala City
Query!
Country [66]
0
0
Guatemala
Query!
State/province [66]
0
0
Guatemala
Query!
Country [67]
0
0
Mexico
Query!
State/province [67]
0
0
Guadalajara
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
Mexico City
Query!
Country [69]
0
0
Mexico
Query!
State/province [69]
0
0
Monterrey
Query!
Country [70]
0
0
Mexico
Query!
State/province [70]
0
0
Zapopan
Query!
Country [71]
0
0
Philippines
Query!
State/province [71]
0
0
Manila
Query!
Country [72]
0
0
South Africa
Query!
State/province [72]
0
0
Amanzimtoti
Query!
Country [73]
0
0
South Africa
Query!
State/province [73]
0
0
Cape Town
Query!
Country [74]
0
0
South Africa
Query!
State/province [74]
0
0
Johannesburg
Query!
Country [75]
0
0
South Africa
Query!
State/province [75]
0
0
Midrand
Query!
Country [76]
0
0
South Africa
Query!
State/province [76]
0
0
Umkomaas
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Alicante
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Barcelona
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Begonte
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Cadiz
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Granollers
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Jaén
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
La Coruna
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Leon
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Madrid
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Pamplona
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Torrelavega
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Valencia
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Vigo
Query!
Country [90]
0
0
Turkey
Query!
State/province [90]
0
0
Antalya
Query!
Country [91]
0
0
Turkey
Query!
State/province [91]
0
0
Canakkale
Query!
Country [92]
0
0
Turkey
Query!
State/province [92]
0
0
Isparta
Query!
Country [93]
0
0
Turkey
Query!
State/province [93]
0
0
Istanbul
Query!
Country [94]
0
0
Turkey
Query!
State/province [94]
0
0
Kartal
Query!
Country [95]
0
0
Turkey
Query!
State/province [95]
0
0
Kayseri
Query!
Country [96]
0
0
Turkey
Query!
State/province [96]
0
0
Kozlu / Zonguldak
Query!
Country [97]
0
0
Turkey
Query!
State/province [97]
0
0
Malatya
Query!
Country [98]
0
0
Turkey
Query!
State/province [98]
0
0
Manisa
Query!
Country [99]
0
0
Turkey
Query!
State/province [99]
0
0
Mecidiyekoy/Istanbul
Query!
Country [100]
0
0
Turkey
Query!
State/province [100]
0
0
Yenisehir/Izmir
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when
combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients
with chronic obstructive pulmonary disease (COPD)
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00846586
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00846586
Download to PDF